trimetrexate has been researched along with Graft vs Host Disease in 2 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the acute toxicity of trimetrexate (TMTX) used in combination with cyclosporine (CsA) for prevention of acute graft-versus-host disease (GVHD) in patients undergoing allogeneic marrow transplantation from HLA-mismatched, related donors." | 9.08 | A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. ( Anasetti, C; Beach, K; Deeg, HJ; Doney, KC; Hansen, JA; Martin, PJ; Nash, RA; Schubert, MM; Storb, R; Sullivan, KM, 1995) |
| "Trimetrexate and CSP were given as noted above." | 5.28 | Use of trimetrexate for the prevention of graft-versus-host disease. ( Appelbaum, FR; Deeg, HJ; Graham, TC; Raff, RF; Sandmaier, B; Schuening, F; Storb, R, 1989) |
| "This study evaluated the acute toxicity of trimetrexate (TMTX) used in combination with cyclosporine (CsA) for prevention of acute graft-versus-host disease (GVHD) in patients undergoing allogeneic marrow transplantation from HLA-mismatched, related donors." | 5.08 | A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. ( Anasetti, C; Beach, K; Deeg, HJ; Doney, KC; Hansen, JA; Martin, PJ; Nash, RA; Schubert, MM; Storb, R; Sullivan, KM, 1995) |
| "Trimetrexate and CSP were given as noted above." | 1.28 | Use of trimetrexate for the prevention of graft-versus-host disease. ( Appelbaum, FR; Deeg, HJ; Graham, TC; Raff, RF; Sandmaier, B; Schuening, F; Storb, R, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doney, KC | 1 |
| Storb, R | 2 |
| Beach, K | 1 |
| Anasetti, C | 1 |
| Deeg, HJ | 2 |
| Hansen, JA | 1 |
| Martin, PJ | 1 |
| Nash, RA | 1 |
| Schubert, MM | 1 |
| Sullivan, KM | 1 |
| Appelbaum, FR | 1 |
| Raff, RF | 1 |
| Graham, TC | 1 |
| Sandmaier, B | 1 |
| Schuening, F | 1 |
1 trial available for trimetrexate and Graft vs Host Disease
| Article | Year |
|---|---|
A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cyclosporine; Drug Therapy, Combination; Graft vs Ho | 1995 |
1 other study available for trimetrexate and Graft vs Host Disease
| Article | Year |
|---|---|
Use of trimetrexate for the prevention of graft-versus-host disease.
Topics: Animals; Antineoplastic Agents; Child; Cyclosporins; Dogs; Drug Combinations; Folic Acid Antagonists | 1989 |